Table 1.
Clinicopathologic features of the 749 patients with nasopharyngeal carcinoma (NPC)
| Feature | No. of patients [cases (%)] |
|---|---|
| Sex | |
| Male | 580 (77.4) |
| Female | 169 (22.6) |
| WHO pathology | |
| Type I | 5 (0.7) |
| Type II/III | 744 (99.3) |
| Clinical stagea | |
| I–II | 257 (34.3) |
| III–IV | 492 (65.7) |
| T stagea | |
| T1 | 177 (23.6) |
| T2 | 140 (18.7) |
| T3 | 264 (35.2) |
| T4 | 168 (22.4) |
| N stagea | |
| N0 | 184 (24.6) |
| N1 | 409 (54.6) |
| N2 | 106 (14.2) |
| N3 | 50 (6.7) |
| Chemotherapy | |
| No chemotherapy | 214 (28.6) |
| Concurrent | 243(32.5) |
| Induction + concurrent | 246 (32.8) |
| Concurrent + adjuvant | 46 (6.1) |
WHO World Health Organization
aAccording to the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system